Fixed-Dose Combination Medication for Dyspnea Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute and persistent dyspnea, particularly in patients with heart failure or non-cardiac causes, often fail to effectively manage respiratory rate and oxygen saturation in the long term, leading to high readmission rates and mortality, with limited therapeutic options for persistent dyspnea and suboptimal use of heart failure oral therapies post-discharge.
Innovation Solution
A combination medication comprising at least three compounds: a beta blocker, a renin-angiotensin-aldosterone system inhibitor (ACE inhibitor, angiotensin II inhibitor, or ARNi), a mineralocorticoid receptor antagonist, an SGLT2 inhibitor (dapagliflozin or empagliflozin), and a diuretic, administered to patients with elevated BNP or NT-proBNP levels and congestion, to restore and maintain respiration rate and oxygen saturation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard single-agent or dual-agent therapy is used for acute and persistent dyspnea, then treatment simplicity is maintained, but therapeutic effectiveness and patient outcomes deteriorate
Solution Approach 1:
The patent combines multiple heart failure medications (beta-blocker, ACE inhibitor/ARB/ARNI, MRA, SGLT2 inhibitor, and diuretic) into a single fixed-dose combination pill. This merging approach maintains therapeutic effectiveness by ensuring all necessary agents are administered together at optimal doses, while simplifying the treatment regimen for patients to just one daily pill instead of multiple separate medications.
Solution Approach 2:
The fixed-dose combination pill serves multiple therapeutic functions simultaneously: it provides neurohormonal blockade (beta-blocker, ACE inhibitor/ARB/ARNI, MRA), promotes natriuresis (SGLT2 inhibitor), and manages fluid overload (diuretic). This multi-functionality in a single agent addresses the complex pathophysiology of heart failure and persistent dyspnea without requiring multiple separate treatments.
2Ease of operation
If multiple heart failure medications are administered separately, then dosage flexibility is maintained, but patient compliance and long-term management deteriorate
Solution Approach 1:
By merging five different heart failure medications into a single fixed-dose combination pill, the patent dramatically improves patient compliance. Patients only need to take one pill daily instead of managing multiple separate medications with different dosing schedules, which reduces medication errors and improves adherence to the treatment regimen.
Solution Approach 2:
The fixed-dose combination pill is designed with pre-determined optimal dosages of each component medication based on clinical trial data. This preliminary action of establishing optimal doses in advance eliminates the need for patients and clinicians to navigate complex dosing decisions, ensuring that patients receive the most effective combination from the start.
3Reliability
If conventional treatments are used for persistent dyspnea, then immediate symptom relief may be achieved, but readmission rates and mortality increase
Solution Approach 1:
The fixed-dose combination pill provides continuous neurohormonal blockade and hemodynamic optimization through its five component medications. This continuous action addresses both acute symptoms and underlying pathophysiology, preventing disease progression and reducing the risk of hospital readmission and mortality over the long term.
Solution Approach 2:
The patent establishes optimal dosages of all five medications in the fixed-dose combination based on preliminary clinical trials (such as the EMPEROR-Reduced trial). This preliminary optimization ensures that patients receive the most effective treatment regimen from the outset, maximizing long-term outcomes rather than starting with suboptimal therapy that would require later adjustments.
Data Source
AI summary
Subject matter of the present invention is a combination medication for use in the treatment of a patient having acute and/or persistent dyspnea comprising at least two of the following components: a beta blocker, and one agent of the group consisting of an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II inhibitor and a combination of angiotensin II inhibitor or an angiotensin receptor-neprilysin inhibitor (ARNi), and mineralo receptor antagonist (MRA), gliflozine, a loop-acting diuretic, wherein a sample of bodily fluid of said patient has a level of BNP>200 pg/mL and/or has a level NT-proBNP>600 pg/mL, and wherein said sample of bodily fluid is selected from the group comprising blood, plasma and serum, and wherein said patient is either a patient with heart failure with left ventricular ejection fraction (LVEF) greater and equal to 40%, preferably 50%, or a patient with no heart failure.